证券研究报告：宏观报告 发布时间：2025-06-09 研究所 分析师:袁野 SAC 登记编号:S1340523010002 Email:yuanye@cnpsec.com 研究助理:苑西恒 SAC 登记编号:S1340124020005 Email:yuanxiheng@cnpsec.com 近期研究报告 《5 月制造业生产活力提升，稳需求政 策发力空间打开》 - 2025.06.03 宏观研究 美关税不确定下，日元资产的演化路径 核心观点 （1）美国关税政策成为 9 月日本加息关键变量，利差交易平仓 或冲击全球资产 近三年日本通胀居高不下，一直维持在日本央行 2%的通胀目标水 平之上，特别是进入 2025 年以来，日本 CPI 同比增速处于 3.5%以上 水平，日本核心 CPI 同比增速亦保持在 3%以上，成为制约日本内需的 重要因素。日本通胀的根源在哪？是大米等食品价格推升，还是工资 -通胀螺旋自我强化机制的确立？这不仅决定了日本通胀的可持续 性，亦会影响日本央行货币政策的操作。 日本通胀高企，工业产品是主要支撑，大米等农产品并非主要推 动力。从商品和服务两个维度来看，日本商品价格高涨是日本通胀高 企的 ...

证券研究报告：金融工程报告 发布时间：2025-06-09 研究所 研究所 分析师:肖承志 SAC 登记编号:S1340524090001 Email:xiaochengzhi@cnpsec.com 研究助理:金晓杰 SAC 登记编号:S1340124100010 E研ma究il所:jinxiaojie@cnpsec.com 近期研究报告 近期研究报告 《结合基本面和量价特征的 GRU 模型》 - 2025.06.05 《DeepSeek-R1 完成小版本更新，阿里 开源自主搜索 AI 智能体——AI 动态汇 总 20250602》 - 2025.06.03 《Claude 4 系列发布，谷歌上线编程智 能体 Jules——AI 动态汇总 20250526》 - 2025.05.27 《谷歌发布智能体白皮书，Manus 全面 开放注册——AI 动态汇总 20250519》 - 2025.05.20 《证监会修改《重组办法》，深化并购重 组改革——微盘股指数周报 20250518》 - 2025.05.19 《通义千问发布Qwen-3模型，DeepSeek 发布数理证明大模型——AI 动态汇总 20250505 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" [1] Core Viewpoints - Indonesia is considering the procurement of Chinese-made J-10 fighter jets, which is expected to boost the military trade market's activity. The Indonesian government aims to enhance its air force's modernization while ensuring cost-effectiveness in its defense budget. The performance of the J-10 in the India-Pakistan conflict is a significant factor in Indonesia's consideration of this model. Compared to Western counterparts, the J-10 offers a more competitive price and meets Indonesia's demand for "high cost-performance advanced equipment" [10][12][14] - The report suggests that China's military trade, currently accounting for 5.9% of the global military trade market, has the potential for significant growth as China increasingly takes center stage on the world stage [12][14] - Looking ahead to 2025, the military industry is expected to see an inflection point in orders, driven by new technologies aimed at enhancing equipment performance or reducing costs, as well as new market directions from military trade and military technology conversion [14] Summary by Sections 1. Industry Overview - The closing index for the defense industry is at 1508.79, with a 52-week high of 1712.48 and a low of 1113.62 [1] 2. Market Performance - The military industry index increased by 0.07%, while the Shenwan military index rose by 0.41%. The Shanghai Composite Index increased by 1.13%, and the Shenzhen Component Index rose by 1.42% [16] - The top ten performing stocks in the military sector this week include Xinguang Optoelectronics (+10.62%), Huawu Co., Ltd. (+9.71%), and Longda Co., Ltd. (+9.21%) [18] 3. Investment Recommendations - Two main investment themes are suggested: 1) Aerospace and "gap-filling" new focuses, including companies like Feilihua, Fenghuo Electronics, and AVIC Shenyang Aircraft [14] 2) New technologies, products, and markets with greater elasticity, including Aerospace Intelligent Manufacturing and Guangdong Hongda [14] 4. Valuation Levels - As of June 6, 2025, the military industry index stands at 10727.13, with a PE-TTM valuation of 103.35 and a PB valuation of 3.29. Historically, 79.75% of the time since January 1, 2014, the PE-TTM valuation has been below the current level [21][22]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14]. - The pharmaceutical and biotechnology sector has shown a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18]. Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14]. - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15]. 2. Subsector Performance - The pharmaceutical sector's sub-indices all recorded gains, with the raw materials and blood products sectors leading with a 2.89% increase [7][22]. - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26]. 3. Recommended and Beneficiary Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihe Jiaye, among others [8]. - Beneficiary stocks identified are Shanhaishan, Yirui Technology, and Lianying Medical [27]. 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI applications in imaging and surgery [26]. - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29]. - **IVD Sector**: The report notes a 2.00% increase in the IVD sector, with a focus on AI-assisted diagnostics [30]. - **Blood Products**: The blood products sector is experiencing a 2.89% increase, with ongoing consolidation and product diversification [31]. - **Retail Pharmacy**: The offline pharmacy sector is expected to benefit from improved operational efficiencies through AI integration [34]. - **Healthcare Services**: The hospital sector has seen a 1.07% increase, with growth in specific medical fields like ophthalmology and reproductive health [36]. - **Traditional Chinese Medicine**: The sector is expected to recover as the impact of previous procurement policies diminishes [38]. - **CXO Sector**: The report indicates a positive outlook for the CXO sector, driven by increased demand for outsourcing in drug development [40].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14] - The pharmaceutical and biotechnology sector has seen a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18] Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14] - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15] 2. Subsector Performance - The pharmaceutical and biotechnology sector has shown positive performance across all sub-sectors, with the raw materials and blood products sectors leading with a 2.89% increase [7][22] - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26] 3. Recommended and Benefiting Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihua Jiaye, among others [8] - Benefiting stocks from the current trends include Shanhaishan, Yirui Technology, and Lianying Medical [8][27] 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI integration in imaging and surgical applications [26] - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29] - **IVD Sector**: The in vitro diagnostics sector is anticipated to recover as AI technologies enhance diagnostic capabilities [30] - **Blood Products**: The blood products sector is experiencing stable demand, with a projected 10.9% increase in plasma collection in 2024 [31] - **Retail Pharmacy**: The retail pharmacy sector is expected to see improved performance as market conditions stabilize and AI technologies enhance operational efficiency [34] - **Healthcare Services**: The healthcare services sector is showing signs of recovery, particularly in ophthalmology and reproductive health services [36] - **Traditional Chinese Medicine**: The sector is expected to benefit from improved consumer sentiment and demand for high-quality OTC products [38] - **CXO Sector**: The CXO sector is entering an upward cycle as companies report improved order growth and performance [40]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1] Core Viewpoints - Indonesia is considering the procurement of Chinese-made J-10 fighter jets, which is expected to boost the military trade market's activity [10][14] - China's military trade currently accounts for 5.9% of the global military trade market, significantly lower than the US at 43% and Russia at 9.6% [12][14] - The military industry is anticipated to see an inflection point in orders as it enters the second half of the "Centenary Goal of Building a Strong Army" by 2025, with new technologies and products expected to create new market directions [14] Summary by Sections 1. Industry Overview - The closing index for the defense industry is at 1508.79, with a 52-week high of 1712.48 and a low of 1113.62 [1] 2. Investment Suggestions - Two main investment themes are suggested: 1. Aerospace and "gap-filling" new focuses, including companies like Feilihua, Fenghuo Electronics, and AVIC Shenfei [14] 2. New technologies, products, and markets with greater elasticity, including companies like Aerospace Intelligent Manufacturing and Guangdong Hongda [14] 3. Market Performance - The military industry index saw a slight increase of 0.07%, while the broader market indices showed higher gains, indicating a relatively weaker performance in the military sector [16] - The top ten performing stocks in the military sector this week included Xinguang Optoelectronics (+10.62%) and Huawu Co., Ltd. (+9.71%) [18] 4. Valuation Levels - As of June 6, 2025, the military industry index stands at 10727.13, with a PE-TTM valuation of 103.35 and a PB valuation of 3.29 [21] - Historical data shows that 79.75% of the time since January 1, 2014, the PE-TTM valuation has been lower than the current level [21] 5. Data Tracking - Recent data tracking includes information on private placements and stock incentive plans for various military companies, indicating active capital movements within the sector [24][26]

证券研究报告：国防军工|点评报告 行业投资评级 强于大市|维持 行业点评：硝化棉需求旺盛，出口量价齐升 | 行业基本情况 | | --- | | 收盘点位 | 1508.79 | | --- | --- | | 52 周最高 | 1712.48 | | 52 周最低 | 1113.62 | 行业相对指数表现（相对值） -13% -8% -3% 2% 7% 12% 17% 22% 27% 32% 2024-06 2024-08 2024-11 2025-01 2025-03 2025-06 国防军工 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:鲍学博 SAC 登记编号:S1340523020002 Email:baoxuebo@cnpsec.com 分析师:王煜童 SAC 登记编号:S1340523070004 Email:wangyutong@cnpsec.com 近期研究报告 《中邮军工周报 5 月第 4 周：美国防预 算将达 1 万亿美元，创历史新高》 - 2025.05.26 事件 2025 年 1-4 月，我国硝化棉出口数量为 760 万吨，同比增长 39%； 出口金额为 2.50 亿 ...

2024-06 2024-08 2024-10 2025-01 2025-03 2025-06 -12% -9% -6% -3% 0% 3% 6% 9% 12% 15% 18% 电力 沪深300 证券研究报告：电力|点评报告 发布时间：2025-06-09 行业投资评级 强于大市 |维持 行业基本情况 | | 收盘点位 | 3165.47 | | --- | --- | --- | | 52 | 周最高 | 3359.79 | | 52 | 周最低 | 2868.51 | 资料来源：聚源，中邮证券研究所 研究所 行业相对指数表现（相对值） 分析师:杨帅波 SAC 登记编号:S1340524070002 Email:yangshuaibo@cnpsec.com 近期研究报告 《南方区域电力市场运行规则进一步 完善，看好虚拟电厂对绿电运营商的赋 能》 - 2025.06.04 国家首个绿电直连规则发布，有望破除欧盟绿色贸 易壁垒 l 投资要点 事件：根据储能头条，2025 年 5 月 21 日，国家发改委、国家能 源局发布《关于有序推动绿电直连发展有关事项的通知》。 l 中国绿电直连相关政策 2025 年 2 月 ...

证券研究报告：国防军工|点评报告 行业投资评级 强于大市|维持 | 行业基本情况 | | --- | | 收盘点位 | 1508.79 | | --- | --- | | 52 周最高 | 1712.48 | | 52 周最低 | 1113.62 | 研究所 分析师:鲍学博 SAC 登记编号:S1340523020002 Email:baoxuebo@cnpsec.com 分析师:王煜童 SAC 登记编号:S1340523070004 Email:wangyutong@cnpsec.com 行业相对指数表现（相对值） -13% -8% -3% 2% 7% 12% 17% 22% 27% 32% 2024-06 2024-08 2024-11 2025-01 2025-03 2025-06 国防军工 沪深300 资料来源：聚源，中邮证券研究所 近期研究报告 《中邮军工周报 5 月第 4 周：美国防预 算将达 1 万亿美元，创历史新高》 - 2025.05.26 行业点评：硝化棉需求旺盛，出口量价齐升 事件 2025 年 1-4 月，我国硝化棉出口数量为 760 万吨，同比增长 39%； 出口金额为 2.50 亿 ...

证券研究报告：金融工程报告 发布时间：2025-06-09 研究所 分析师:肖承志 SAC 登记编号:S1340524090001 Email:xiaochengzhi@cnpsec.com 研究助理:李子凯 SAC 登记编号:S1340124100014 Email:lizikai@cnpsec.com 近期研究报告 《结合基本面和量价特征的 GRU 模型》 - 2025.06.05 《综合金融受益于稳定币表现突出， ETF 资金逢高净流出医药和消费——行 业轮动周报 20250601》 – 2025.06.02 《退潮周期情绪仍需等待恢复，ETF 净 流 入 国 防 军 工 — — 行 业 轮 动 周 报 20250525》 – 2025.05.26 《ETF 大幅流出红利，成长 GRU 行业因 子得分提升较大——行业轮动周报 20250518》 – 2025.05.19 《各大宽基指数成功补缺，融资资金大 幅净流出银行，GRU 模型偏防守——行 业轮动周报 20250511》 - 2025.05.12 《上证指数振幅持续缩小，目标仍为补 缺，机器人 ETF 持续净流入——行业轮 动周报 20250504 ...